RHD and rheumatic heart disease: Based on the idea that anti-tumor as well as anti-RhD IgG Abs should induce a strong ADCC response by recruiting FcγRIIIA-expressing immune cells, the French biotechnology company Laboratoire Francais du Fractionnement et des Biotechnologies (LFB; Les Ulis, France) has generated a monoclonal anti-CD20 IgG1 Ab (ublituximab; LFB-R603) and a human monoclonal RhD-specific IgG1 Ab (roledumab, LFB-R59330) with low Fc fucosylation, low Fc galactosylation and low Fc sialylation based on their patent31.